<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>De Bari B</dc:creator>
  <dc:creator>Lestrade L</dc:creator>
  <dc:creator>Franzetti-Pellanda A</dc:creator>
  <dc:creator>Jumeau R</dc:creator>
  <dc:creator>Biggiogero M</dc:creator>
  <dc:creator>Kountouri M</dc:creator>
  <dc:creator>Matzinger O</dc:creator>
  <dc:creator>Miralbell R</dc:creator>
  <dc:creator>Bourhis J</dc:creator>
  <dc:creator>Ozsahin M</dc:creator>
  <dc:creator>Zilli T</dc:creator>
  <dc:date>2018</dc:date>
  <dc:description xmlns:ns0="xml" ns0:lang="en">PURPOSE
To report outcomes of a population of anal cancer patients treated with modern intensity-modulated radiotherapy and daily image-guided radiotherapy techniques.


METHODS
We analyzed data of 155 patients consecutively treated with intensity-modulated radiotherapy +/- chemotherapy in three radiotherapy departments. One hundred twenty-two patients presented a stage II-IIIA disease. Chemotherapy was administered in 138 patients, mainly using mitomycin C and 5-fluorouracil (n = 81). All patients received 36 Gy (1.8 Gy/fraction) on the pelvic and inguinal nodes, on the rectum, on the mesorectum and on the anal canal, and a sequential boost up to a total dose of 59.4 Gy (1.8 Gy/fraction) on the anal canal and on the nodal gross tumor volumes.


RESULTS
Median follow-up was 38 months (interquartile range 12-51). Toxicity data were available for 143 patients: 22% of them presented a G3+ acute toxicity, mainly as moist desquamation (n = 25 patients) or diarrhea (n = 10). Three patients presented a late grade 3 gastrointestinal toxicity (anal incontinence). No grade 4 acute or late toxicity was recorded. Patients treated with fixed-gantry IMRT delivered with a sliding window technique presented a significantly higher risk of acute grade 3 (or more) toxicity compared to those treated with VMAT or helical tomotherapy (38.5 vs 15.3%, p = 0.049). Actuarial 4-year local control rate was 82% (95% CI 76-91%).


CONCLUSIONS
Modern intensity-modulated radiotherapy with daily image-guided radiotherapy is effective and safe in treating anal cancer patients and should be considered the standard of care in this clinical setting.</dc:description>
  <dc:format>application/pdf</dc:format>
  <dc:identifier>https://sonar.ch/global/documents/232661</dc:identifier>
  <dc:language>eng</dc:language>
  <dc:relation>info:eu-repo/semantics/altIdentifier/doi/10.1007/s00432-018-2608-6</dc:relation>
  <dc:relation>info:eu-repo/semantics/altIdentifier/pmid/29441419</dc:relation>
  <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
  <dc:source>Journal of cancer research and clinical oncology. - 2018</dc:source>
  <dc:subject xmlns:ns1="xml" ns1:lang="en">Anal cancer</dc:subject>
  <dc:subject xmlns:ns2="xml" ns2:lang="en">Helical tomotherapy</dc:subject>
  <dc:subject xmlns:ns3="xml" ns3:lang="en">IMRT</dc:subject>
  <dc:subject xmlns:ns4="xml" ns4:lang="en">Local control</dc:subject>
  <dc:subject xmlns:ns5="xml" ns5:lang="en">Toxicity</dc:subject>
  <dc:subject xmlns:ns6="xml" ns6:lang="en">VMAT</dc:subject>
  <dc:subject xmlns:ns7="xml" ns7:lang="en">Aged</dc:subject>
  <dc:subject xmlns:ns8="xml" ns8:lang="en">Anus Neoplasms</dc:subject>
  <dc:subject xmlns:ns9="xml" ns9:lang="en">Chemoradiotherapy</dc:subject>
  <dc:subject xmlns:ns10="xml" ns10:lang="en">Female</dc:subject>
  <dc:subject xmlns:ns11="xml" ns11:lang="en">Humans</dc:subject>
  <dc:subject xmlns:ns12="xml" ns12:lang="en">Male</dc:subject>
  <dc:subject xmlns:ns13="xml" ns13:lang="en">Middle Aged</dc:subject>
  <dc:subject xmlns:ns14="xml" ns14:lang="en">Radiotherapy, Intensity-Modulated</dc:subject>
  <dc:subject xmlns:ns15="xml" ns15:lang="en">Randomized Controlled Trials as Topic</dc:subject>
  <dc:title xmlns:ns16="xml" ns16:lang="en">Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients.</dc:title>
  <dc:type>http://purl.org/coar/resource_type/c_6501</dc:type>
</oai_dc:dc>
